You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)受惠多項利好消息帶動逆市續漲18% A股漲停
復星醫藥(02196.HK)受惠於一連串利好消息帶動,今天(21日)股價四連升,下午2時過後股價曾急抽高至41.95元(暫受制牛熊線44.4元),創近四個月高,現報39.7元,急漲18%,成交急增至3,982萬股,涉資14.85億元;A股復星醫藥(600196.SH)漲停,收55.52元人民幣。 復星醫藥上周五(18日)公布,就共同出資設立蘇州星盛園豐創業投資合夥企業,該目標基金已在中國證券投資基金業協會完成私募投資基金備案。同時,公布控股子公司復星醫藥產業已收到國家藥品監督管理局關於同意其獲許可引進的一種新型腫瘤免疫治療藥SVN53-67/M57-KLH(月太)疫苗(即SurVaxM)聯合替莫唑胺輔助治療初診的膠質母細胞瘤開展臨床試驗批准。 復星醫藥產業上周底表示,已獲非獨家許可生產免費仿製輝瑞新冠口服藥。此外,復星醫藥上周尾表示,控股子公司「復宏漢霖」自主研發用於治療晚期腫瘤HLX301注射液內地臨床試驗獲批。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account